XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment revenues:        
Total revenues $ 35,290 $ 42,569 $ 119,222 $ 142,540
Segment gross profit:        
Total segment gross profit 17,728 23,639 67,953 83,142
Unallocated:        
Research and development (50,977) (46,833) (152,423) (130,279)
Sales and marketing (10,349) (9,109) (30,213) (27,276)
General and administrative (24,824) (23,890) (73,901) (73,414)
Gain on equity investments 0 0 0 147,322
Change in fair value 25,459 (14,522) 27,763 61,869
Other income 4,737 5,804 14,363 13,067
Income tax benefit (expense) 90 2,887 (449) (3,041)
Consolidated net (loss) income (38,136) (62,024) (146,907) 71,390
Software        
Segment revenues:        
Total revenues 31,884 28,904 100,703 90,469
Segment gross profit:        
Total segment gross profit 23,405 21,870 77,081 69,625
Drug discovery        
Segment revenues:        
Total revenues 3,406 13,665 18,519 52,071
Segment gross profit:        
Total segment gross profit $ (5,677) $ 1,769 $ (9,128) $ 13,517